Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Says Fiscal Q2 Revenues Grow 6 Percent As R&D Spending Surges and Profits Fall

NEW YORK, April 26 (GenomeWeb News) - Becton Dickinson today said that total revenues for its fiscal second quarter increased 6.1 percent as R&D spending surged 96 percent and profits declined.

 

Total receipts for the three months ended March 31 increased to $1.45 billion from $1.37 billion year over year. Revenue from the BD Biosciences unit grew 7.7 percent to $219 million year over year, the second-highest growth this period from among the company's three divisions.

 

R&D spending increased to $129 million from $66 million in the year-ago period, the company said.

 

Profits declined to $154 million, or $.63 per share, from $188.2 million, or $.74 per share, year over year.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.